Quantcast

Latest Fluticasone/salmeterol Stories

2008-10-29 15:00:10

PHILADELPHIA, Oct. 29 /PRNewswire-FirstCall/ -- GlaxoSmithKline announced today that data from a three-year study of patients with Chronic Obstructive Pulmonary Disease (COPD) found that the inhaled corticosteroid in Advair Diskus 250/50, fluticasone propionate, did not show an adverse effect on bone mineral density (BMD) measured at the lumbar spine and total hip compared to salmeterol alone. In this study, designed to show equivalent rate of change in BMD for Advair and salmeterol,...

2008-10-23 03:00:40

SkyePharma Announces Successful Completion of FlutiformTM U.S. Clinical Trial Programme LONDON, UK, 23 October, 2008 - SkyePharma PLC (LSE: SKP) today announces that the final U.S. Phase III efficacy study evaluating FlutiformTM for the treatment of moderate to severe asthma in adolescent and adult patients has met its primary endpoint. The study is the last Phase III clinical efficacy study to be carried out in preparation for regulatory filing. In a top line analysis of key results, the...

2008-09-09 12:00:42

Sepracor, a research-based pharmaceutical company, has announced that Alvesco HFA inhalation aerosol metered-dose inhaler is now available by prescription in the US. Alvesco HFA is a new inhaled corticosteroid indicated for maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older. This asthma treatment is available in 80mcg/actuation and 160mcg/actuation dosage strengths. Adrian Adams, president and CEO of Sepracor, said: "Our...

2008-08-05 12:01:07

Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue. Stakeholder Insight: Asthma - Over-prescribing is common in intermittent and mild forms of asthma http://www.reportlinker.com/p091764/Stakeholder-Insight-Asthma---Over-prescribing-is-common-in-intermittent-and-mild-forms-of-asthma.html Introduction Asthma is managed using a step-wise approach, with bronchodilators to relieve symptoms of airflow...

2008-07-22 03:00:42

SkyePharma Announces Positive Results for Two European Studies for Flutiform(TM) LONDON, UK 22 July 2008 - SkyePharma PLC (LSE: SKP) today announces that its development and marketing partner Mundipharma has successfully completed two Phase III clinical studies for the European development programme for Flutiform(TM), both of which show positive results. Study FLT-3501 assessed 182 patients, suffering from mild to moderate-severe persistent and reversible...

2008-07-02 06:01:01

By Gillissen, Adrian To the Editor: I read with interest the article by Dr. Wedzicha and colleagues (1) wherein the authors compared clinical efficacy of a 104-week treatment with salmeterol/fluticasone propionate fixed combination (SFC) with a treatment with tiotropium bromide in chronic obstructive pulmonary disease (COPD). However, a few important aspects regarding the severity of COPD in the recruited patients and the interpretation of the results merit further attention. First, the...

2007-12-27 03:00:11

By Karpel, Jill P Nelson, Harold Key words: Asthma - Dry powder inhaler - Inhaled corticosteroids - Mometasone furoate - Prednisone ABSTRACT Background: Mometasone furoate (MF), a potent synthetic inhaled corticosteroid (ICS) with a high affinity for the glucocorticoid receptor, is approved for use in the treatment of asthma. Scope: Publications reviewed in this article were identified via searches of MEDLINE and EMBASE databases using the terms 'mometasone furoate AND pharmacology' and...

2007-09-16 06:00:10

By Buhl, R Vogelmeier, C Key words: Asthma - Budesonide/formoterol - Budesonide/ formoterol maintenance and reliever therapy - Exacerbations - Salmeterol/fluticasone ABSTRACT Background: fisi inhaled corticosteroid (ICS) or an ICS/ long- acting beta2-agonist (LABA) combination plus short-acting ss^sub 2^- agonist (SABA) as needed for symptom relief is recommended for persistent asthma. Additionally, budesonide/formoterol maintenance and reliever therapy (Symbicort SMART, AstraZeneca,...

2007-06-11 09:00:10

RESEARCH TRIANGLE PARK, N.C., June 11 /PRNewswire/ -- GlaxoSmithKline announced today the nationwide availability of two formulations of an inhaled corticosteroid (ICS) with a dose counter -- Flovent(R) HFA 44 mcg (fluticasone propionate 44 mcg inhalation aerosol) and Flovent(R) Diskus(R) 50 mcg (fluticasone propionate inhalation powder) -- for children ages four and older with mild, persistent asthma. The new dose counter feature on these products will provide parents and children with an...

2007-06-10 06:00:11

By Doull, Iolo Price, David; Thomas, Mike; Hawkins, Neil; Et al Key words: Asthma - Cost-effectiveness - Fluticasone/salmeterol - Quality of life ABSTRACT Objective: To determine where in the treatment steps recommended by the British Thoracic Society and Scottish Intercollegiate Guidelines Network (BTS/SIGN) Asthma Guideline it is cost-effective to use salmeterol xinafoate/fluticasone propionate combination inhaler (SFC) (Seretide*) compared with other inhaled corticosteroid (ICS)...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related